Your Tech Dose From Now: Twice A Day After Meals
DataQuest|September 2021
Pharma experts have given a prescription to gear up for the arrival of the new normal. The needle is moving towards digital twins, cloud, and AI in a big way
Pratima Harigunani

As per the Annual Technology Vision Trends Report, 83% organisations are accelerating transformation, 99% are ranking the pandemic as an unprecedented stress test, and 100% are innovating with a call to action. Laggards must really catch up or they will be left behind, unravelled Ankur Aggarwal, MD, Technology, Accenture India.

Speaking at the Dataquest webinar on ‘Technology Vision for Life Sciences’, Aggarwal stressed that it is a once-in-a-generation re-platforming opportunity. “The window to do so is very small. Leaders will leap forward over laggards.”

Yes, pharma companies have been in the spotlight like never before in the last two years. But for them, the spotlight was on technology. The way in which and the place where they invest in technology are going through a visceral change.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM DATAQUESTView All

Energy & Utility Sector Plugs Into New-Age Digital Solutions

As India gears up to meet the climate challenge, the energy sector is undergoing a radical transformation. Many new technologies will be crucial in this change

8 mins read
DataQuest
October 2021

It's Time To Change! Here's How To Do It

The pandemic has been a great opportunity for radical transformation - of ourselves and our businesses. Here are some playbooks for an organisational change

5 mins read
DataQuest
October 2021

Going Digital? Don't Forget To Build Cyber Citadels

As technologies get weaponised, users must adopt a multilayer approach that anticipates cyberattacks and safeguards critical assets before they are exploited

3 mins read
DataQuest
October 2021

Choose the right metrics for your SaaS portfolio

With the onset of everything digital, organisations are applying datadriven techniques across their business processes to get that 5-star customer rating

3 mins read
DataQuest
October 2021

OPEN THE BANK WINDOWS, PLEASE

Open banking is like a Pandora's Box that opens up many questions and disruptions, which both banks and their fintech neighbours need to face

10 mins read
DataQuest
October 2021

How Al can come to the aid of farmers

Computer Vision, part of Al, can bring about radical changes in agriculture, increasing yields and incomes. It's time farming became a high-tech industry

3 mins read
DataQuest
October 2021

Marching towards a multi-cloud future

While cloud has proved to be a major enabler for business continuity and transformation, as seen in the pandemic, it's time to step up to a multi-cloud phase

3 mins read
DataQuest
October 2021

RAPIDLY CHANGING ENVIRONMENT REQUIRES ADAPTABILITY QUOTIENTW

While climate change and cyber-threats are keeping risk management experts busy, they are also aware of governance issues and the specific flip-side of hyper-personalisation for insurance companies. All this, when they are ready to embrace big data, Al and models to make their jobs faster and easier. Andrew D. Rallis, Global Chief Actuary, MetLife, and the immediate past president of the Society of Actuaries, gives some back-of-the-envelope calculations on the formula between technology and risk management in this interview. He also explains why it's time for not just IQ or EQ but also AQ. Excerpts:

4 mins read
DataQuest
October 2021

POST-COVID WILL BE MORE FOCUSED ON CONTEXTUAL DATA SCIENCE

It is trying to fill a white space in the renewable space that not many have addressed so far. It manages over 5 GW of energy assets across the globe already. So what is it exactly that a sharper eye - or shall we say Alye - can do for a wind or solar energy park? P Rajasekaran, Chief Products Officer, Bahwan CyberTek helps us understand that while also covering some old and new challenges that surround Analytics. Excerpts from an interview:

4 mins read
DataQuest
October 2021

Tech tips to keep supply chains moving

The pandemic has created a crisis for manufacturers around the world, affecting operations and supply chains. Thankfully, technology has solutions for each stage

4 mins read
DataQuest
October 2021
RELATED STORIES

Coming Out Of The Chemical Closet

Neuropsychopharmacologist Carl Hart says most of what the public knows about drugs is both scary and wrong.

10+ mins read
Reason magazine
May 2021

Business at Its Best

With a big hand from the government, pharmaceutical companies delivered the vaccine that the world desperately needed. Here’s how something in 2020 went right for a change

10+ mins read
Bloomberg Businessweek
December 28 - January 04, 2021

Vintage Pharmacy Cabinet

An Homage to the Past by Embracing the Present.

10+ mins read
Popular Woodworking
December 2020

Bitter Pill

We need covid-19 treatments asap—but a perverse incentive could slow pharma breakthroughs.

5 mins read
Mother Jones
July/August 2020

All Eyes On Gilead

Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. Gilead Sciences was ready

10+ mins read
Bloomberg Businessweek
May 18, 2020

How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes

How patient-assistance funds give drug companies cover to raise prices.

10+ mins read
Bloomberg Businessweek
May 23 - May 29, 2016

Under Fire From Washington, Pharma Is Fighting to Repair Its Reputation

As Washington considers limiting consumer pharmaceutical advertising, the industry tries to burnish its image. 

9 mins read
ADWEEK
March 28, 2016

Purple reign

It’s September and the grapes hang heavy on the vine, ripe for treading, explains Amy Jeffs

2 mins read
Country Life UK
September 01, 2021

GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B

While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.

10+ mins read
Bio Spectrum
September 2021

“WE PROVIDE SEAMLESS DATA INTEGRATION”

Umesh Pai, Managing Director, EPLAN Software & Services Pvt Ltd, speaks about how the company is addressing the requirements of digitalisation, standardisation and automation

4 mins read
The Machinist
August 2021